OMER · Omeros Corporation

The thesis

Omeros Corporation's case still depends on one result: YARTEMLEA, its drug for the transplant complication TA-TMA (transplant-associated thrombotic microangiopathy), has to grow sales for a second straight quarter. The third-quarter 2026 report, expected around 12 November 2026, settles it. Net product sales need to beat the second quarter's $28.5 million.

The case is unchanged since the 7 October 2026 note, and the shares have firmed. They closed at $19.12 on 8 October 2026, up from $18.51 on 6 October 2026, according to adjusted daily closes. That close is 9.2% below the $21.05 52-week high and 91.0% above the price three months earlier.

The narrative is maturing: the launch is widely covered, Omeros has issued no new results or guidance since its 12 August 2026 second-quarter release, and Cantor Fitzgerald's 22 September 2026 upgrade remains the last new source of attention. The third quarter ended on 30 September 2026 and was the first full quarter under YARTEMLEA's permanent billing code. Medicare's New Technology Add-on Payment (NTAP) began on 1 October 2026, so it can lift fourth-quarter sales but not the quarter about to be reported.

Bullish and bearish views on Omeros Corporation

The bull case on Omeros Corporation (OMER), in brief: Second-quarter sales nearly tripled. The bear case: Two launch quarters are thin evidence.

Bull case

• Second-quarter sales nearly tripled. Omeros reported Q2 2026 net product sales of $28.5 million against $9.9 million in Q1 in its 12 August 2026 results release. Gross revenue was $32.2 million against $11.1 million, and Omeros described the quarter's inventory build at hospitals as low, Stock Titan reported.
• Billing was simpler for all of Q3. A permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA took effect on 1 July 2026, according to Omeros. Hospitals and outpatient centers no longer bill the drug under a temporary or miscellaneous code.
• Medicare pays extra from October. The Centers for Medicare & Medicaid Services (CMS) granted YARTEMLEA NTAP status from 1 October 2026. Omeros said on 3 August 2026 that the add-on pays up to $287,079 for each eligible Medicare inpatient case.
• A broker models a much larger market. Cantor Fitzgerald upgraded Omeros from Neutral to Overweight on 22 September 2026 with a $22 target, Benzinga reported. The firm forecasts peak US sales of $400 million and a 35% to 40% market share. H.C. Wainwright's target is $33, cut from $40 after the June European setback.
• The business reached break-even. Omeros reported Q2 2026 operating income of $0.1 million and net income of $13.2 million, or $0.18 per share. Management said on the 12 August 2026 call that YARTEMLEA had 73 unique ordering accounts at 30 June 2026.

Bear case

• Two launch quarters are thin evidence. Q1 and Q2 2026 are the only reported sales figures, too few to set a growth rate. Omeros gave no revenue guidance on the 12 August 2026 call, citing limited experience with prescribing trends.
• An insider sold near the high. Vice president of finance and chief accounting officer David Borges exercised options and sold 20,000 shares at $20.95 on 22 September 2026 and 23 September 2026, worth $419,000, Investing.com reported. The sale ran under a 10b5-1 trading plan adopted on 10 February 2026.
• Europe has not approved the drug. The European Medicines Agency's drug committee, the CHMP, issued a negative opinion on narsoplimab for TA-TMA on 26 June 2026. Omeros asked for a re-examination with review by an independent expert group; it has not announced an outcome or a date.
• Debt costs still weigh on cash. Omeros held $132.0 million in cash and short-term investments at 30 June 2026, then spent $60.2 million in July to repurchase $30.5 million of convertible-note principal. It guided to about $6.5 million of Q3 interest expense on the 12 August 2026 call.
• One product carries the whole company. Essentially all revenue comes from YARTEMLEA in TA-TMA, so a stall in hospital reorders has no offset.

Price setup

The shares closed at $19.12 on 8 October 2026, according to adjusted daily closes. That is 9.2% below the $21.05 52-week high, set around the time of the September insider sale at $20.95, and 91.0% above the close three months earlier. The 14-day relative strength index (RSI), a momentum gauge running from 0 to 100, stood at 58.7, in the middle of its range.

The close sits below Cantor Fitzgerald's $22 target and well below H.C. Wainwright's $33 target. The pullback from the September high has been orderly so far: the shares have held between $18.51 and $19.12 in the latest sessions. The research invalidation is a weekly close below $16.00, a level well under the 8 October 2026 close of $19.12 and the $21.05 high.

Crowding is moderate. The three-month gain is large, and an insider sold into the September strength. The earnings date is about five weeks away, outside the next 30 days, and no share issuance has been announced.

Catalysts, next 30 days

• 12 October to 15 October 2026: CHMP monthly meeting. The European committee meets in Amsterdam. Omeros has not said whether the narsoplimab re-examination concludes at this meeting; a positive reversal would open Europe, while a confirmed negative leaves the US case intact.
• ~12 November 2026, est.: Q3 2026 results. This falls just outside the 30-day window but decides the case. It is the first full quarter under the permanent J-code, and net product sales above $28.5 million would confirm a second quarter of growth. Omeros has not yet announced the date.

What would change the view

The case breaks if Q3 2026 net product sales come in at or below Q2's $28.5 million. That result would point to second-quarter stocking rather than repeat demand. A share offering, or Q3 cash and short-term investments falling well below the $132.0 million reported at 30 June 2026, would also weaken the case by adding dilution risk to a single-product launch.

On price, a weekly close below $16.00 would end the thesis. That level sits well under the $19.12 close of 8 October 2026.

The case would strengthen if Q3 sales clearly exceed $28.5 million with unique ordering accounts above the 73 reported at 30 June 2026. A reversal of the European opinion would add a second market.

What it trades with

Omeros shares trade mainly on company-specific events: the stock rose about 20% on the 12 August 2026 second-quarter report, according to Investing.com's coverage of the call. Its moves have tracked YARTEMLEA reimbursement, sales and European regulatory news more than broad market direction. As a small single-product biotech, it can still move with risk appetite for small-cap biotechnology, but the next large move is likely to come from the Q3 report or the CHMP outcome.